A practical reference on ESI-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-05. Anything still debated is marked as such rather than presented as settled.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
An especially strong Walker circulation causes La Niña, which is considered to be the cold oceanic and positive atmospheric phase of the broader El Niño–Southern Oscillation (ENSO) weather phenomenon, as well as the opposite of El Niño weather pattern, where sea surface temperature across the eastern equatorial part of the central Pacific Ocean will be lower than normal by 3–5 °C (5.4–9 °F). The phenomenon occurs as strong winds blow warm water at the ocean's surface away from South America, across the Pacific Ocean towards Indonesia. As this warm water moves west, cold water from the deep sea rises to the surface near South America. The movement of so much heat across a quarter of the planet, and particularly in the form of temperature at the ocean surface, can have a significant effect on weather across the entire planet. Tropical instability waves visible on sea surface temperature maps, showing a tongue of colder water, are often present during neutral or La Niña conditions. La Niña is a complex weather pattern that occurs every few years, often persisting for longer than five months. El Niño and La Niña can be indicators of weather changes across the globe. Atlantic and Pacific hurricanes can have different characteristics due to lower or higher wind shear and cooler or warmer sea surface temperatures.
Molecular biomarkers have been defined as biomarkers that can be discovered using basic and acceptable platforms such as genomics and proteomics. Many genomic and proteomics techniques are available for biomarker discovery and a few techniques that are recently being used can be found on that page. Apart from genomics and proteomics platforms biomarker assay techniques, metabolomics, lipidomics, glycomics, and secretomics are the most commonly used as techniques in identification of biomarkers. Biomarkers can be classified on their clinical applications as molecular biomarkers, cellular biomarkers or imaging biomarkers. Four of the main types of molecular biomarkers are genomic biomarkers, transcriptomic biomarkers, proteomic biomarkers and metabolic biomarkers.
Research has been ongoing since the 1960s to determine the proportion of 14C in the atmosphere over the past 50,000 years. The resulting data, in the form of a calibration curve, is now used to convert a given measurement of radiocarbon in a sample into an estimate of the sample's calendar age. Other corrections must be made to account for the proportion of 14C in different types of organisms (fractionation), and the varying levels of 14C throughout the biosphere (reservoir effects). Additional complications come from the burning of fossil fuels, such as coal and oil, and from the above-ground nuclear tests done in the 1950s and 1960s. Because the time it takes to convert biological materials to fossil fuels is substantially longer than the time it takes for their 14C to decay below detectable levels, fossil fuels contain almost no 14C. As a result, beginning in the late 19th century, there was a noticeable drop in the proportion of 14C as the carbon dioxide generated from burning fossil fuels began to accumulate in the atmosphere. Conversely, nuclear testing increased the amount of 14C in the atmosphere, which reached a maximum in about 1965 of almost double the amount present in the atmosphere prior to nuclear testing. Measurement of radiocarbon was originally done by beta-counting devices, which counted the amount of beta radiation emitted by decaying 14C atoms in a sample.
Sources: en.wikipedia.org
== Drug interactions == The amounts of alpha-tocopherol, other tocopherols, and tocotrienols that are components of dietary vitamin E, when consumed from foods, do not appear to cause any interactions with drugs. Consumption of alpha-tocopherol as a dietary supplement in amounts in excess of 300 mg/day may lead to interactions with aspirin, warfarin, tamoxifen and cyclosporine A in ways that alter function. For aspirin and warfarin, high amounts of vitamin E may potentiate anti-blood clotting action. In multiple clinical trials, vitamin E lowered blood concentration of the immunosuppressant medication cyclosporine A. The US National Institutes of Health, Office of Dietary Supplements, raises a concern that co-administration of vitamin E could counter the mechanisms of anti-cancer radiation therapy and some types of chemotherapy, and so advises against its use in these patient populations. The references it cites report instances of reduced treatment adverse effects, but also poorer cancer survival, raising the possibility of tumor protection from the intended oxidative damage by the treatments.
For services to the Post Office and to the community in Scunthorpe, Lincolnshire. Marion Constance Harrison. For services to the Schizophrenia Fellowship on Jersey. Maureen Hart, Personal Secretary, Vickers Defence Systems Ltd. For services to the Defence Industry. Patricia Mary Hart. For services to the community on Alderney. William Mark Hartley. For services to the community in Coventry. Dorothy Elizabeth Hawes, Vocal Department Consultant, Trinity College of Music, London. For services to Music Education. Judith Anne Hawkshaw. For services to Housing and the community in Suffolk. Shirley Caroline Amelia Hawley, lately Nursing Assistant, Pease Hill Residential Unit, Nottingham Healthcare Trust. For services to Health Care. Dinnie Margaret Hawthorne. For services to the community, particularly Elderly People in Bourne End, Buckinghamshire. Gordon Charles Hay, Gas Engineer. For humanitarian services to the former Yugoslavia. Arthur Rowland Hayter. For charitable services in Waterlooville, Hampshire. Desmond Heard, Gas Engineer. For humanitarian services to the former Yugoslavia. Albert Maurice Heath. For services to the Nevill Hall Hospital League of Friends, Abergavenny, Gwent. Alison Helen Constance Heath, Curator, the British Library. For services to Librananship and to Deaf People. Barbara Ceha Heath. For services to the community in Ringmer, East Sussex. Leslie Heath, Publican. For services to the community in East London. Patricia Ann Hedges, Education Advisor, Parcelforce. For services to the Freight Industry.
Although spironolactone poses an important risk of hyperkalemia in the elderly, in those with kidney or cardiovascular disease, and/or in those taking medications or supplements, which increase circulating potassium levels, a large retrospective study found that the rate of hyperkalemia in young women without such characteristics who had been treated with high doses of spironolactone for dermatological conditions did not differ from those of controls. This was the conclusion of a 2017 hybrid systematic review of studies of spironolactone for acne in women, as well, which found that hyperkalemia was rare and was invariably mild and clinically insignificant. These findings suggest that hyperkalemia may not be a significant risk in such individuals, and that routine monitoring of circulating potassium levels may be unnecessary in this population. Other sources have claimed that hyperkalemia can nonetheless also occur in people with more normal renal function and presumably without such risk factors. Occasional testing on a case-by-case basis in those with known risk factors may be justified. Side effects of spironolactone that may be indicative of hyperkalemia and if persistent could justify serum potassium testing include nausea, fatigue, and particularly muscle weakness. Notably, reduced or no routine potassium monitoring with spironolactone in young women would reduce costs associated with its use. Among young, gender-diverse individuals taking spironolactone, hyperkalemia is rare and (if present) transient and asymptomatic.
==== Works ==== A.A.A (EP), by Nigerian band A.A.A AAA (Lee Hwi-min album), 2022 AAA (Hyukoh and Sunset Rollercoaster album), 2024 Access All Areas (EP), by The AAA Girls, 2017 Access All Areas (Flo album), 2024, including a song titled "AAA" "AAA", a song on City (Strapping Young Lad album), 1997 "Aaa", a song by They Might Be Giants on their 2015 album Glean Greek: "ΑΑΑ (ΑΑΑ) και χωρίσαμε", romanized: AAA (AAA) kai korisame, lit. 'AAA (AAA) and we broke up', a song on Kravgi by Anna Vissi, 2000
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.